Vor Biopharma (VOR) Competitors $0.87 +0.00 (+0.29%) (As of 11:27 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends VOR vs. CMPX, MGNX, SLDB, STRO, ADCT, XBIT, DMAC, SOPH, TRVI, and INBXShould you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Compass Therapeutics (CMPX), MacroGenics (MGNX), Solid Biosciences (SLDB), Sutro Biopharma (STRO), ADC Therapeutics (ADCT), XBiotech (XBIT), DiaMedica Therapeutics (DMAC), SOPHiA GENETICS (SOPH), Trevi Therapeutics (TRVI), and Inhibrx (INBX). These companies are all part of the "pharmaceutical products" industry. Vor Biopharma vs. Compass Therapeutics MacroGenics Solid Biosciences Sutro Biopharma ADC Therapeutics XBiotech DiaMedica Therapeutics SOPHiA GENETICS Trevi Therapeutics Inhibrx Vor Biopharma (NYSE:VOR) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations. Which has more risk and volatility, VOR or CMPX? Vor Biopharma has a beta of -0.37, suggesting that its stock price is 137% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Do analysts recommend VOR or CMPX? Vor Biopharma currently has a consensus target price of $11.36, suggesting a potential upside of 1,206.92%. Compass Therapeutics has a consensus target price of $6.75, suggesting a potential upside of 306.63%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Vor Biopharma is more favorable than Compass Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vor Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Compass Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media refer more to VOR or CMPX? In the previous week, Compass Therapeutics had 1 more articles in the media than Vor Biopharma. MarketBeat recorded 2 mentions for Compass Therapeutics and 1 mentions for Vor Biopharma. Compass Therapeutics' average media sentiment score of 0.94 beat Vor Biopharma's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, VOR or CMPX? Compass Therapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVor BiopharmaN/AN/AN/A-$1.65-0.53Compass TherapeuticsN/AN/A-$42.49M-$0.37-4.49 Do insiders & institutionals have more ownership in VOR or CMPX? 97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 4.7% of Vor Biopharma shares are held by company insiders. Comparatively, 28.5% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is VOR or CMPX more profitable? Vor Biopharma's return on equity of 0.00% beat Compass Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vor BiopharmaN/A N/A N/A Compass Therapeutics N/A -32.37%-30.67% Does the MarketBeat Community believe in VOR or CMPX? Vor Biopharma received 19 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 73.17% of users gave Compass Therapeutics an outperform vote while only 68.06% of users gave Vor Biopharma an outperform vote. CompanyUnderperformOutperformVor BiopharmaOutperform Votes4968.06% Underperform Votes2331.94% Compass TherapeuticsOutperform Votes3073.17% Underperform Votes1126.83% SummaryVor Biopharma beats Compass Therapeutics on 8 of the 14 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VOR vs. The Competition Export to ExcelMetricVor Biopharma IndustryMedical SectorNYSE ExchangeMarket Cap$57.14M$2.11B$5.21B$20.56BDividend YieldN/A15.10%5.23%3.44%P/E Ratio-0.5310.5686.2536.62Price / SalesN/A195.131,470.3319.18Price / CashN/A90.7135.2818.69Price / BookN/A1.534.935.74Net IncomeN/A$69.09M$117.66M$984.43M7 Day Performance8.62%0.64%2.86%0.64%1 Month Performance7.98%5.66%1.79%6.66%1 Year Performance-54.74%14.57%35.89%24.58% Vor Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VORVor Biopharma1.8074 of 5 stars$0.87+0.3%$11.36+1,203.2%-54.7%$59.85MN/A-0.53140Gap UpCMPXCompass Therapeutics3.5458 of 5 stars$1.68+2.8%$6.75+303.0%-1.8%$230.46M$850,000.00-4.4920Positive NewsMGNXMacroGenics4.2453 of 5 stars$3.66+1.9%$7.63+108.3%-56.0%$229.70M$58.75M-2.27430Positive NewsSLDBSolid Biosciences3.544 of 5 stars$5.73+0.5%$15.14+164.3%+92.4%$228.97M$8.09M-1.88100Gap UpSTROSutro Biopharma4.6471 of 5 stars$2.77+4.5%$12.14+338.4%+0.0%$228.41M$153.73M-1.65240Positive NewsGap UpADCTADC Therapeutics2.1852 of 5 stars$2.34-3.3%$8.25+252.6%+109.0%$226.26M$70.72M-1.01310XBITXBiotech0.5659 of 5 stars$7.36-3.3%N/A+79.6%$224.33M$4.01M0.00100DMACDiaMedica Therapeutics2.4775 of 5 stars$5.18-8.5%$7.00+35.1%+106.2%$221.50MN/A-9.3620Positive NewsGap DownSOPHSOPHiA GENETICS1.8253 of 5 stars$3.38-0.9%$6.50+92.3%-15.4%$220.97M$64.49M-3.09520TRVITrevi Therapeutics3.9673 of 5 stars$2.86-0.7%$7.43+159.7%+157.7%$219.84MN/A-6.5520Positive NewsINBXInhibrx1.2867 of 5 stars$15.16-0.7%N/A-32.6%$219.46M$1.57M0.00166Short Interest ↑Positive NewsGap Up Related Companies and Tools Related Companies CMPX Competitors MGNX Competitors SLDB Competitors STRO Competitors ADCT Competitors XBIT Competitors DMAC Competitors SOPH Competitors TRVI Competitors INBX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:VOR) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
